Walmsley: GSK Will Take Incremental Deal-Making Approach In Building Up Oncology
GSK has more than doubled its oncology pipeline since July 2018, and the company's CEO thinks smaller deals and a new site combining R&D and manufacturing will enable its progress to continue.
You may also be interested in...
GlaxoSmithKline said its increasingly streamlined operations are on a growth trajectory, but that capacity constraints mean demand for its popular shingles vaccine will keep outstripping supply.
Tender deadline for Roche acquisition of Spark pushed back to 30 October; 21.4% of Spark shares tendered so far. Vertex further diversifies with fourth deal of 2019 – an RNA-targeted collaboration with Ribometrix.
The DREAMM-2 trial of the antibody-drug conjugate belantamab mafodotin in relapsed/refractory multiple myeloma patients has hit its primary endpoint, giving GSK a chance to file for approval before its BCMA rivals.